AQIA.US AQIA
- Market cap
- USD 7.39M
- P/E
- -
- P/B
- 0.00x
- ROE
- -3.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is AQIA.US undervalued?
Graham numberThe Graham number of AQIA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AQIA fundamental analysis
No fundamental analysis for AQIA yet.
AQIA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AQIA
Aquiva Group Inc., through its subsidiary, Aquiva Medical Inc., engages in the commercialization of AquiForm, a proprietary, versatile topical materials platform based on its novel Hydrogel with inter-Penetration Network Anchor (HiPNA) vehicle for consumer health, wellness, and cosmetics; medical device; and therapeutics and transdermal drug-delivery systems. The company was formerly known as BHPA, INC. and changed its name to Aquiva Group Inc. in May 2025. The company was i…
Full company profileAQIA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
AQIA annual financial statements
| Item | 2008 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | 1.88M | 241K | - | - | - | 31.5K | - | - |
| Gross Profit | - | - | - | -76.0K | -759K | - | - | - | - | - | - |
| Operating Income | -136K | -5.00K | -60.0K | -267K | -894K | -658K | -27.5K | -57.8K | -181K | -131K | -22.0K |
| EBITDA | -136K | -5.00K | -60.0K | 109K | -488K | 1.14M | 242K | -1.81M | -181K | -131K | -22.0K |
| Net Income | -136K | -5.00K | -60.0K | -63.2K | -694K | 907K | 13.3K | -1.97M | -181K | -131K | -22.0K |
| EPS | -0.06 | 0.00 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 8.04M | - | - | 2.49M | 1.76M | 2.68M | 2.71M | 5.72K | 4.27M | 4.27M | 803K |
| Total Liabilities | 4.95M | - | 27.4K | 704K | 671K | 678K | 697K | 34.5K | 23.2K | 151K | 161K |
| Shareholders' Equity | 3.09M | - | -27.4K | 1.78M | 1.09M | 2.00M | 2.01M | -28.8K | 4.25M | 4.12M | 642K |
| Cash & Short-term Investments | 531K | - | - | 629K | 125K | 10.6K | 2.28K | 3.26K | 7.06K | 3.61K | 2.58K |
| Total Debt | 500K | - | 27.4K | 698K | 669K | 669K | 689K | 8.41K | 23.2K | 79.2K | 112K |
| Cash Flow | |||||||||||
| Operating Cash Flow | 3.49M | - | -27.4K | -1.16M | -705K | 13.4K | -28.4K | -7.47K | -204K | -74.5K | -68.4K |
| Capital Expenditure | 650K | - | 0.00 | 0.00 | 3.00 | 0.00 | 0.00 | 4.00 | 4.00 | 0.00 | 6.00 |
| Free Cash Flow | 2.84M | - | -27.4K | -1.16M | -705K | 13.4K | -28.4K | -7.47K | -204K | -74.5K | -68.4K |
| Ratios | |||||||||||
| ROE | -4.4% | - | - | -3.5% | -63.7% | 45.4% | 0.7% | - | -4.2% | -3.2% | -3.4% |
| ROA | -1.7% | - | - | -2.5% | -39.4% | 33.9% | 0.5% | -34,527.9% | -4.2% | -3.1% | -2.7% |
| Net Profit Margin | - | - | - | -3.4% | -288.2% | - | - | - | -572.7% | - | - |
| Debt to Equity | 0.16x | - | - | 0.39x | 0.61x | 0.33x | 0.34x | - | 0.01x | 0.02x | 0.18x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
AQIA dividends
AQIA has not paid dividends in the last 9 fiscal years.
Last stock split: 1:70 on May 22, 2025.
Who owns AQIA
Ownership data of AQIA is not available yet.
AQIA company profile
- Company name
- AQIA
- Ticker
- AQIA.US
- Exchange
- USA Stocks
- Sector
- Technology
- Industry
- Software - Application
- Employees
- 2
- Fiscal year end
- March
- Address
- #3 Bethesda Metro Cente, Bethesda, MD, United States, 20814
- Phone
- 202 536 5191
- Website
- aquivamedical.com
About AQIA
Aquiva Group Inc., through its subsidiary, Aquiva Medical Inc., engages in the commercialization of AquiForm, a proprietary, versatile topical materials platform based on its novel Hydrogel with inter-Penetration Network Anchor (HiPNA) vehicle for consumer health, wellness, and cosmetics; medical device; and therapeutics and transdermal drug-delivery systems. The company was formerly known as BHPA, INC. and changed its name to Aquiva Group Inc. in May 2025. The company was incorporated in 2005 and is based in Bethesda, Maryland.
AQIA management
2- Mr. James J. PierceCFO, Principal Accounting Officer & Treasurer · born 1976
- Mr. David CravenSecretary & Director · born 1957